Necrobiosis Lipoidica Therapy with Biologicals: An Ulcerated Case Responding to Etanercept and a Review of the Literature

Suárez-Amor, Óscar; Pérez‐Bustillo, A.; Ruíz‐González, Inmaculada; Rodríguez-Prieto, Manuel Ángel

doi:10.1159/000314694

Cited by 59 publications

(50 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 Suspicion of early NL warrants referral to a dermatologist for diagnostic confirmation. Reid et al summarised the evidence for the various therapeutic approaches in a recent review.…”

Section: Treatmentmentioning

confidence: 99%

Necrobiosis lipoidica

George

Walton

2015

Br J Diabetes

View full text Add to dashboard Cite

Necrobiosis lipoidica and granuloma annulare are granulomatous skin conditions that have been traditionally associated with diabetes mellitus, although recently the strength of association has been questioned. In the first section of this two-part article, we describe the suggested aetiology, clinical features, histology and treatment of necrobiosis lipoidica. It is found in 0.3% of patients with diabetes, but has also been reported with other systemic conditions. Clinically it appears as a waxy, atrophic, yellowish plaque with overlying telangiectasia and a brown border. Although usually asymptomatic, it may be extremely painful, especially if ulcerated. Squamous cell carcinoma has occasionally been reported with longstanding lesions. Treatment is often difficult: numerous topical and systemic agents have been employed, but evidence is limited to small case series and individual case reports. Br J Diabetes 2016;16:6-9

show abstract

“…23 Suspicion of early NL warrants referral to a dermatologist for diagnostic confirmation. Reid et al summarised the evidence for the various therapeutic approaches in a recent review.…”

Section: Treatmentmentioning

confidence: 99%

Necrobiosis lipoidica

George

Walton

2015

Br J Diabetes

View full text Add to dashboard Cite

show abstract

“…Treatment of ulcerative lesions is challenging and often unsuccessful. [50]. There have been some other reports of NL treated with etanercept.…”

Section: -Necrobiosis Lipoidicamentioning

confidence: 99%

“…A review of the published literature suggests that etanercept should be considered as a therapeutic alternative mainly in ulcerative NL unresponsive to prior conventional regimens. The dose and duration of treatment with these agents is not defined, therefore it is required to report management of these patients in order to develop an optimal therapeutic strategy [50].…”

Section: -Necrobiosis Lipoidicamentioning

confidence: 99%

“…It is important to stress to patients that HS is neither caused by poor hygiene nor contagious. Because surgical intervention can be disfiguring and not entirely curative, clinicians have pursued alternative treatment modalities [50,51].…”

Section: -Hidradenitis Suppurativamentioning

confidence: 99%

“…Randomized, double-blinded, placebo-controlled trials are needed to better elucidate the future of these drugs for the treatment of HS. If conventional treatment options fail, the use of etanercept can be a useful supplement for the treatment of recurrent severe HS [50,51].…”

Section: -Hidradenitis Suppurativamentioning

confidence: 99%

See 2 more Smart Citations

Off-Label Dermatological Uses of Etanercept Treatment

2016

J turk acad dermatol

View full text Add to dashboard Cite

Background: Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine that plays an immunomodulatory role in a variety of systemic and dermatologic disease. Its blockade can be achieved by using specific inhibitors like etanercept. At present, etanercept is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis and psoriasis treatment. However, it has been used with promising results in other inflammatory dermatoses. Etanercept treatment have been reported in the following dermatologic diseases: sarcoidosis, hidradenitis suppurativa, acne vulgaris, cicatricial pemphigoid, pemphigus vulgaris, Hailey-Hailey disease, Behçet' s disease, oral aphthous stomatitis, pyoderma gangrenosum, multicentric reticulohistiocytosis, apthous stomatitis, Sneddon-Wilkinson disease, acrodermatitis continua of Hallopeau, SAPHO syndrome, pityriasis rubra pilaris, vitiligo, necrobiosis lipoidica, silicone granulomas, Sweet's syndrome, atopic dermatitis, dyshidrotic eczema, toxic epidermal necrolysis, alopecia areata, centrifugal annular erythema, primary amyloidosis, erythroderma-related pruritus in Sézary syndrome, cutaneous T-cell lymphoma, inflammatory linear verrucous epidermal nevus, excessive scarring, postherpetic neuralgia, dermatomyositis, vasculitis, lupus erythematosus, and scleroderma. The vast majority of these reports are in the form of individual case reports and small case series. A growing number of published reports suggest that etanercept treatment may be effective in the treatment of numerous inflammatory skin disease outside their currently approved indications.

show abstract

The Skin in Diabetes

Sharpe

Yesudian

2016

Textbook of Diabetes

View full text Add to dashboard Cite

Necrobiosis Lipoidica Therapy with Biologicals: An Ulcerated Case Responding to Etanercept and a Review of the Literature

Cited by 59 publications

References 52 publications

Necrobiosis lipoidica

Necrobiosis lipoidica

Off-Label Dermatological Uses of Etanercept Treatment

The Skin in Diabetes

Contact Info

Product

Resources

About